- In April 2025, the UC San Diego Center for Microbiome Innovation announced Haleon as a new industry partner. This collaboration aims to unite CMI's microbiome expertise with Haleon's science and clinical capabilities to accelerate microbiome discoveries through joint research programs, especially exploring solutions for consumer health areas such as healthy aging, cardiovascular health, and general well-being
- In May 2024, Vedanta Biosciences announced the enrollment of the first patient in its pivotal Phase 3 RESTORATiVE303 study of VE303, an orally administered defined bacterial consortium candidate for the prevention of recurrent C. difficile infection. This significant step highlights the ongoing progression of defined consortium approaches, moving beyond donor-derived therapies
- In January 2024, Vedanta Biosciences Inc. announced a significant collaboration with an academic institution to delve deeper into the gut microbiome’s intricate role in metabolic health and explore its potential for therapeutic applications. This partnership aims to leverage cutting-edge research to develop novel approaches for metabolic disorders
- In April 2023, Ferring Pharmaceuticals received FDA approval for REBYOTA (fecal microbiota, live – jslm), a microbiota-based live therapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI. This approval was a key milestone, providing a ready-to-use formulation
- In March 2023, Seres Therapeutics received FDA approval for Vowst (formerly SER-109), the first orally administered microbiota-based therapeutic for the prevention of recurrent Clostridioides difficile infection (CDI) in adults. This landmark approval marked a significant advancement in microbiome medicine, offering a new treatment option for a challenging condition
